Prospective randomised trial comparing diethylstilboestrol and flutamide in the treatment of hormone relapsed prostate cancer

International Journal of Urology

Volumn 9, Issue 8, 2002, Pages 431-434

  Burns Cox, N ^c   Basketter, V ^a   Higgins, B ^b   Holmes, S ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

^b QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^c NONE

Author keywords

Antiandrogen; Diethylstilboestrol; Hormone relapsed prostate cancer; Survival

Indexed keywords

ACETYLSALICYLIC ACID; DIETHYLSTILBESTROL; FLUTAMIDE;

AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CASTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; INTERVIEW; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; TREATMENT OUTCOME;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; DIETHYLSTILBESTROL; FLUTAMIDE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 0036379736     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2042.2002.00495.x     Document Type: Article

References (13)

1. Bishop MC. Experience with low-dose oestrogen in the treatment of advanced prostate cancer: a personal view. Br. J. Urol. 1996; 78: 921-8.
2. Robertson CN, Roberson KM, Padilla GM et al. Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. J. Natl Cancer Inst. 1996; 88 (13): 908-17.
3. Carruba G, Miceli D, D'Amico D et al. Sex steroids upregulate e-cadharin expression in hormone responsive LNCaP human prostate cancer cells. Biochem. Biophys. Res. Commun. 1995; 212: 624-31.
4. Farrugia D, Ansell W, Singh M, Philp T, Chinegwundoh F, Oliver RT. Stilboestrol plus adrenal suppression as salvage treatment for patients failing treatment with luteinizing hormone-releasing hormone analogues and orchidectomy. Br. J. Urol. Int. 2000; 85: 1069-73.
5. Byar DP. The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 1973; 32: 1126-13.
6. Leuprolide Study Group. Leuprolide versus diethylstilboestrol for metastatic prostate cancer. N. Engl. J. Med. 1984; 311: 1281-6.
7. Chang A, Yeap B, Davis T et al. Double-blind, randomised study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilboestrol. J. Clin. Oncol. 1996; 14 (8): 2250-7.
8. Labrie F. Benefits of combination therapy with flutamide in patients relapsing after castration. Br. J. Urol. 1988; 61: 341-6.
9. Fossa SD, Slee PH, Brausi M et al. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: A phase III study of the European Organisation for Research and Treatment of Cancer genitourinary group. J. Clin. Oncol. 2001; 19 (1): 62-71.
10. Kent JR, Bischoff AJ, Arduino LJ et al. Estrogen dosage and suppression of testosterone levels in patients with prostatic carcinoma. J. Urol. 1973; 109: 858-60.
11. Stamey TA, Kabalin JN, Ferrari M, Yang N. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients. J. Urol. 1989; 141: 1088.
12. Miller JI, Ahmann FR, Drach GW, Emerson SS, Bottaccini MR. The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. J. Urol. 1992; 147: 956.
13. Zanetti G, Trinchieri A, DelNero A et al. Prognostic significance of prostate-specific antigen in endocrine treatment for prostatic carcinoma. Eur. Urol. 1992; 1 (Suppl. 21): 96.